Supha Pharmachem Limited (BOM:539561)
India
· Delayed Price · Currency is INR 0.410
-0.020 (-4.65%)
At close: Mar 9, 2026
Supha Pharmachem Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 5,269 | 4,053 | 40,417 | 5,098 | 5,048 | 900.34 | Upgrade
|
| Other Revenue | - | - | - | - | - | 0.02 | Upgrade
|
| Revenue | 5,269 | 4,053 | 40,417 | 5,098 | 5,048 | 900.36 | Upgrade
|
| Revenue Growth (YoY) | -84.25% | -89.97% | 692.75% | 1.00% | 460.66% | 3015.21% | Upgrade
|
| Cost of Revenue | 5,114 | 3,981 | 40,014 | 4,939 | 4,985 | 877.51 | Upgrade
|
| Gross Profit | 154.88 | 71.12 | 403.24 | 159.69 | 63.09 | 22.85 | Upgrade
|
| Selling, General & Admin | 17.35 | 18.09 | 21.46 | 16.24 | 11.14 | 6.07 | Upgrade
|
| Other Operating Expenses | 81.26 | 40.73 | 47.24 | 76.29 | 34.19 | 9.57 | Upgrade
|
| Operating Expenses | 98.81 | 59.21 | 69.27 | 94.04 | 46.07 | 16.24 | Upgrade
|
| Operating Income | 56.07 | 11.91 | 333.97 | 65.65 | 17.02 | 6.62 | Upgrade
|
| Interest Expense | - | -26 | -40.24 | -0.72 | -0.7 | -0.11 | Upgrade
|
| Interest & Investment Income | 3.4 | 1.29 | 0.94 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 106.82 | 106.82 | 209.87 | 8.27 | - | 0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | -8.21 | -50.18 | 0 | 0.76 | -1.07 | - | Upgrade
|
| EBT Excluding Unusual Items | 158.08 | 43.84 | 504.54 | 73.96 | 15.25 | 6.53 | Upgrade
|
| Pretax Income | 158.08 | 43.84 | 504.54 | 73.96 | 15.25 | 6.53 | Upgrade
|
| Income Tax Expense | 35.54 | 22.55 | 177.24 | 19.7 | 4.47 | 1.72 | Upgrade
|
| Net Income | 122.54 | 21.29 | 327.3 | 54.26 | 10.78 | 4.81 | Upgrade
|
| Net Income to Common | 122.54 | 21.29 | 327.3 | 54.26 | 10.78 | 4.81 | Upgrade
|
| Net Income Growth | -49.17% | -93.49% | 503.20% | 403.44% | 124.31% | 73.47% | Upgrade
|
| Shares Outstanding (Basic) | 649 | 403 | 403 | 403 | 403 | 403 | Upgrade
|
| Shares Outstanding (Diluted) | 649 | 403 | 403 | 403 | 404 | 404 | Upgrade
|
| Shares Change (YoY) | 9.07% | - | - | -0.12% | -0.03% | 0.14% | Upgrade
|
| EPS (Basic) | 0.19 | 0.05 | 0.81 | 0.13 | 0.03 | 0.01 | Upgrade
|
| EPS (Diluted) | 0.19 | 0.05 | 0.81 | 0.13 | 0.03 | 0.01 | Upgrade
|
| EPS Growth | -53.82% | -93.84% | 503.20% | 404.03% | 124.37% | 73.22% | Upgrade
|
| Free Cash Flow | -10,042 | -11,348 | -741.61 | 204.57 | 112.33 | -102.51 | Upgrade
|
| Free Cash Flow Per Share | -15.48 | -28.14 | -1.84 | 0.51 | 0.28 | -0.25 | Upgrade
|
| Gross Margin | 2.94% | 1.75% | 1.00% | 3.13% | 1.25% | 2.54% | Upgrade
|
| Operating Margin | 1.06% | 0.29% | 0.83% | 1.29% | 0.34% | 0.73% | Upgrade
|
| Profit Margin | 2.33% | 0.53% | 0.81% | 1.06% | 0.21% | 0.53% | Upgrade
|
| Free Cash Flow Margin | -190.59% | -280.03% | -1.84% | 4.01% | 2.23% | -11.39% | Upgrade
|
| EBITDA | 56.27 | 12.3 | 334.54 | 67.16 | 17.76 | 7.22 | Upgrade
|
| EBITDA Margin | 1.07% | 0.30% | 0.83% | 1.32% | 0.35% | 0.80% | Upgrade
|
| D&A For EBITDA | 0.2 | 0.39 | 0.57 | 1.51 | 0.74 | 0.6 | Upgrade
|
| EBIT | 56.07 | 11.91 | 333.97 | 65.65 | 17.02 | 6.62 | Upgrade
|
| EBIT Margin | 1.06% | 0.29% | 0.83% | 1.29% | 0.34% | 0.73% | Upgrade
|
| Effective Tax Rate | 22.48% | 51.43% | 35.13% | 26.63% | 29.33% | 26.39% | Upgrade
|
| Revenue as Reported | 5,417 | 4,161 | 40,628 | 5,098 | 5,048 | 900.36 | Upgrade
|
| Advertising Expenses | - | 0.09 | 3.03 | 0.31 | 2.36 | 0.43 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.